Global Rare Disease Treatment Market
Rare Disease Treatment Market to Achieve USD 228.34 Billion by 2028, Showcasing a Compound Annual Growth Rate of 11.08%
February 02, 2024 10:52 ET | Research and Markets
Dublin, Feb. 02, 2024 (GLOBE NEWSWIRE) -- The "Global Rare Disease Treatment Market (2023-2028) by Therapeutic Area, Drug Type, Drug Class, Mode of Administration, Distribution Channel, and...
Global Orphan Drugs Market
Global Orphan Drugs Research Analysis Report 2023: Growing Approvals of Innovative Orphan Drugs Propel Market Expansion, Biologics Lead the Way - Forecasts to 2034
January 31, 2024 11:22 ET | Research and Markets
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Global Orphan Drugs Market Analysis & Forecast 2024-2034: Market By Drug Type; By Therapy; By Distribution Channel; and By Region" report has been...
22157.jpg
Paroxysmal Nocturnal Hemoglobinuria Treatment Advances with Comprehensive Danicopan Market Forecast to 2032
January 24, 2024 10:44 ET | Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Danicopan Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The global healthcare...
Global Orphan Drugs Market
Emerging Trends in the Orphan Drugs Industry, 2023-2028: Worldwide Market Analysis Featuring Profiles of Leading Players AstraZeneca, Eisai, Bristol Myers Squibb, and Pfizer Among Others
January 17, 2024 10:03 ET | Research and Markets
Dublin, Jan. 17, 2024 (GLOBE NEWSWIRE) -- The "Global Markets for Orphan Drugs" report has been added to ResearchAndMarkets.com's offering. The global orphan drugs market was valued at an...
AB Science receives
AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis
January 15, 2024 12:07 ET | AB Science
PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2036 IN THE TREATMENT OF MASTOCYTOSIS THIS DECISION FURTHER STRENGTHENS MASITINIB’S INTELLECTUAL...
AB Science reçoit un
AB Science reçoit un avis d’acceptation pour le brevet européen couvrant le masitinib jusqu’en 2036 dans le traitement de la mastocytose
January 15, 2024 12:07 ET | AB Science
COMMUNIQUE DE PRESSE AB SCIENCE REÇOIT UN AVIS D'ACCEPTATION POUR LE BREVET EUROPÉEN COUVRANT LE MASITINIB JUSQU'EN 2036 DANS LE TRAITEMENT DE LA MASTOCYTOSE CETTE DÉCISION RENFORCE LA STRATÉGIE DE...
Emergen logo.png
Orphan Drug Market Size Worth USD 488.53 Billion in 2032 | Emergen Research
January 08, 2024 08:59 ET | Emergen Research
Vancouver, Jan. 08, 2024 (GLOBE NEWSWIRE) -- The global orphan drug market size was USD 154.20 Billion in 2022 and is expected to register a rapid revenue CAGR of 12.3 % during the forecast period....
Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option
December 21, 2023 16:00 ET | Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option Closes acquisition of...
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
November 27, 2023 09:00 ET | Biodexa Pharmaceuticals PLC
Cardiff , Nov. 27, 2023 (GLOBE NEWSWIRE) -- 27 November 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to...
Priothera-Logo (002).png
Priothera – US FDA grants Orphan Drug Designation to mocravimod to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematologic malignancies
November 27, 2023 03:00 ET | Priothera
Mocravimod is the only S1P receptor modulator being developed as an adjunctive and maintenance treatment for blood cancers Mocravimod is being investigated in a global registration-enabling Phase 3...